Research output per year
Research output per year
Personal profile
Headline
ASSOCIATE CLINICAL PROFESSOR
Fingerprint
Dive into the research topics where Karen Burke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Nutraceuticals
Burke, K. E., 1 Jan 2024, Cosmeceuticals: Procedures in Cosmetic Dermatology Series, Fourth Edition. Elsevier, p. 270-282 13 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Photodamage: Protection and Reversal with Topical Antioxidants
Burke, K. E., 1 Jan 2024, Textbook of Cosmetic Dermatology. CRC Press, p. 167-187 21 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Antiaging regimens
Burke, K. E., 4 Feb 2022, Cosmetic Dermatology: Products and Procedures. wiley, p. 571-586 16 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
1 Scopus citations -
Skin Cancer Induced by Pollution-Mediated ROS
Burke, K. E., 1 Jan 2022, Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Springer Nature, Vol. 1. p. 35-56 22 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Environmental aging of the skin: new insights
Burke, K. E., 2020, In: Plastic and Aesthetic Research. 7, 59.Research output: Contribution to journal › Review article › peer-review
Open Access9 Scopus citations
Press/Media
-
Akebia Therapeutics drops 3.8% in Week 11 of 2026: SEC Filings, Insider Filings and Financial Highlights
23/03/26
1 item of Media coverage
Press/Media
-
Weekly: Akebia Therapeutics (AKBA: $1.41) drops 3.8% on weak volume; -5.5c [-3.8%]
23/03/26
1 item of Media coverage
Press/Media
-
Akebia Therapeutics surges 14.1% in Week 10 of 2026: SEC Filings, Insider Filings and Financial Highlights
16/03/26
1 item of Media coverage
Press/Media
-
Weekly: Akebia Therapeutics (AKBA: $1.46) surges 14% on thin volume; +18c [14.1%]
16/03/26
1 item of Media coverage
Press/Media
-
Weekly: Akebia Therapeutics (AKBA: $2.55) climbs 4.1%, 2 weeks' volume in a week; +10c [4.1%] Vol Index 1.6 [1 is avg]
10/05/25
1 item of Media coverage
Press/Media